Press Releases

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, is pleased to announce entering into a co-education

GUANGZHOU, China, Oct. 9, 2026 /PRNewswire/ -- MINISO Group Holding Limited (NYSE:MNSO, HKEX: 9896)) ("MINISO", "MINISO Group" or the "Company"), a world-leading IP-driven retailer and operation platform, today on a voluntary basis provided a business update on the latest performance of its flagship brand MINISO. The figures contained in this press release were based on the preliminary review of the Company's operational data.Sales Performance of MINISO Chinese MainlandTotal GMV(1) of MINISO Chinese mainland for the three months ended September 30, 2026 ("26Q3") grew by 25%-30% year over year ("YoY"), accelerating from the first half of 2026, powered by a high-single-digit SSSG(1).MINISO Chi

Thomas Kim to join S&P Global October 19, 2026Steve Kemps to retire at the end of the yearNEW YORK, Oct. 9, 2026 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Thomas Kim as the company's new Chief Legal Officer, effective October 19, 2026. Mr. Kim will report directly to President and Chief Executive Officer (CEO) Martina Cheung and will oversee S&P Global's Legal, Government Affairs, Risk and Compliance function. Mr. Kim is an accomplished legal executive with over 30 years of experience across public company and private practice legal functions. He previously served as Chief Legal Officer and Corporate Secretary for Gartner and Thomson Reuters.Martina Cheung, Pr

BTQ to bring post-quantum security to MoonPay Korea's full-stack on-chain infrastructure for Korean won stablecoins, from issuance to last-mile delivery, connected to MoonPay's global payments networkPost-quantum security across the full stack: BTQ will serve as MoonPay Korea's security partner, helping prepare its Korean won stablecoin infrastructure for quantum-related threats across issuance support, distribution, wallets, settlement, and last-mile delivery to users and merchants. Joint roadmap and Korean banking proof of concept: The companies will develop a phased post-quantum security roadmap and conduct a proof of concept with Korean banking institutions, testing BTQ's Quantum Secure

ROAD TOWN, British Virgin Islands, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (NASDAQ:AUGO) ("Aura" or the "Company") is pleased to announce Q3 2026 preliminary production results from the Company’s six operating mines: Aranzazu, Apoena, Minosa, Almas, Borborema and MSG ("Mineração Serra Grande"). Total production in Q3 2026, at current prices, reached 95,557 gold equivalent ounces ("GEO")1, record high production, with 27% increase compared to the previous quarter and 29% higher when compared to Q3 2025. At constant prices2, Aura’s quarterly production increased by 26% compared to Q2 2026 and increased 25% above Q3 2025. In Q3 2026, sales totaled 93,742 GEO, a 20% increase compa

MIAMI, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Watsco, Inc. (NYSE:WSO) announced today that it has scheduled a conference call to discuss its 2026 third quarter results on Tuesday, October 27, 2026 at 10:00 a.m. (EDT). Prepared remarks regarding the results will be followed by a question-and-answer session with the senior management team.The conference call will be webcast by CCBN's StreetEvents and can be found under the link highlighted on our website at www.watsco.com. The earnings results will be released before the market opens on October 27, 2026. A replay of the conference call will be available on our website. Investors and analysts are encouraged to pre-register for the conference call

LAS VEGAS, Oct. 09, 2026 (GLOBE NEWSWIRE) -- VenHub Global, Inc. (NASDAQ:VHUB) ("VenHub" or the "Company"), a leader in fully autonomous Smart Store technology, today highlighted the continued expansion of its technology innovation program and intellectual property strategy supporting its autonomous retail Smart Store platform. The Company’s current patent portfolio and planned patent filings pipeline reflect a broad approach to advancing the physical, robotic, software, security, and operational technologies required to operate intelligent, unattended retail environments. VenHub’s technology program is focused on the full autonomous retail ecosystem from modular structures and infrastruc

Fleet data reflects growing adoption of autonomous material movement across customer sites, with more than 11,600 missions completed year to date.MOUNTAIN VIEW, Calif., Oct. 9, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today reported continued progress in the deployment and operation of its autonomous vehicle technology across industrial facilities, as manufacturers and logistics operators increasingly explore opportunities to automate repetitive material movement.Through the first nine months of 2026, Cyngn's autonomous fleet completed more than 11,600 missions and traveled over 3,000 kilometers across customer operations. The company's fleet activity expanded across a growing number of indus

MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors. About Alterity Therapeutics Limited  Alterity Therapeutics is a clinical stage biotechnology company dedicated to c

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile SPRING HOUSE, Pa., Oct. 9, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric patients 12 years of age and older (adolescents) with moderate-to-severe plaque psoriasis. These data, presented at Fall Clinical Dermatology (FCD) 2026, demonstrated consist

New and existing customers get our best deal on the new iPhone Duo, up to $1200 off, with eligible trade-in.1Key Takeaways:More confidence with America's Best Guarantee: a promise to always do our best by customers, and to make it right if we don't—when the connection matters, it has to be AT&T.More performance: Experience iPhone on America's largest wireless2 and fiber3 networks, with enhanced network intelligence and near real time insights to keep customers connected to the right network at the right time.More value and flexibility: New and existing customers can upgrade or switch to AT&T and get up to $1200 off with eligible iPhone trade-in.1 With AT&T Next Up Anytime® customers can get

Richard H. Fearon Appointed Non-Executive Chairman of the BoardReaffirms Full Year and Third Quarter 2026 Financial GuidanceCLEVELAND, Oct. 9, 2026 /PRNewswire/ -- Avient Corporation (NYSE:AVNT), a leading provider of specialized and sustainable material solutions, today announced that its Board of Directors has appointed Mike Frank as President and Chief Executive Officer, effective immediately. Mr. Frank, who has served as CEO of UPL Corporation ("UPL") since 2022, succeeds Dr. Ashish K. Khandpur, who has stepped down from his role and will remain in an advisory capacity through December 31, 2026 to help facilitate a seamless transition. In connection with this appointment, the Board has e

BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of October 5, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 70,150 shares of

Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction in total lesions, and 77% reduction in inflammatory lesions, and was generally well-toleratedClinical findings and preclinical mechanistic evidence support FASN inhibition as a novel oral therapeutic approach targeting key aspects of acne pathogenesisAURORA U.S. Phase 3 trial screening patients, with sites activated and IRB approvals in place FOSTER CITY, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol

WELTRUZA™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses, no oral supplementation and no post-injection monitoring requiredThe approval is based on results from the pivotal Phase 3 SOLARIS trial, which demonstrated overall symptom improvement, significant reduction in illness severity and improvement in personal and social functioning, with a systemic safety profile consistent with oral olanzapine1As Teva drives forward its Pivot to Growth strategy, the company continues to deliver on its commitment to patient-cente

Pebblebrook Hotel Trust (NYSE:PEB) (the "Company" or "Pebblebrook") announced today that on October 8, 2026, it completed the sale of The Hotel Zags, a 174-room hotel in Portland, Oregon, for $10.0 million to a third party. For the trailing twelve months ended August 31, 2026, the hotel’s estimated net operating loss was ($0.8) million, after an assumed annual capital reserve of 4.0% of total hotel revenues, and its estimated hotel earnings before interest, taxes, depreciation, and amortization ("EBITDA") was ($0.6) million. Pebblebrook expects to use the sale proceeds for general corporate purposes, including opportunistically repurchasing the Company’s common or preferred shares and s

BOSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET. The Investor Day will feature discussions with X4 Pharmaceuticals management and key opinion leaders on mavorixafor as a potential treatment for chronic neutropenia. Management will review the current status of the Phase 3 4WARD clinical trial and will outline a planned Phase 2 clinical trial of mavorixafor in combination with granulocyte colony-stimulating factor (G-CSF), designed to assess patients' abi

SHENZHEN, China, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ:JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services, today announced that it has partnered with Yunnan Shennong Agricultural Industry Group Co., Ltd. (605296.SS) ("Shennong Group") to deploy JPush, its intelligent push notification solution, and provide reliable messaging infrastructure supporting Shennong Group’s digital agriculture initiatives. Modern agriculture is undergoing a significant shift toward digital and intelligent operations. As a nationally recognized leading agricultural enterprise, Shennong Group operates an integrated business

GREAT NECK, N.Y., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (NASDAQ:LOAN) announced that its Board of Directors has approved an increase in the aggregate number of shares authorized for repurchase under its existing common share repurchase program from 100,000 to 250,000 common shares and extended the program for an additional twelve months. The manner, timing and number of shares purchased will be at the Company’s discretion. About Manhattan Bridge Capital, Inc. Manhattan Bridge Capital, Inc. offers short-term secured, non–banking loans (sometimes referred to as "hard money" loans) to real estate investors to fund their acquisition, renovation, rehabilitation or

MONTVALE, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Third quarter results will be published prior to the market opening on Friday, October 23, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial community are invited to join the live call by